Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12705055 | 1.00 | APP (1.00) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL12705295 | 0.97 | APP (0.94) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL12705283 | 0.93 | APP (1.00) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL12710245 | 0.93 | APP (0.86) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL12705285 | 0.92 | APP (1.00) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL12705275 | 0.89 | APP (0.80) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL19751933 | 0.88 | CYP1A2 (0.84) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL19751999 | 0.84 | APP (0.72) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL12705279 | 0.83 | APP (0.71) | APPCYP1A2HRH3LMNAALDH1A1 | |
| SCHEMBL19752005 | 0.82 | APP (0.70) | APPCYP1A2HRH3LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488513-B1 | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases | AC IMMUNE SA (CH) | 2017-12-27 | — | — | EP | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | AC IMMUNE S.A. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | AC IMMUNE S.A. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8916590-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE SA (CH) | 2014-12-23 | — | — | US | disclosed |
| US-8916590-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE SA (CH) | 2014-12-23 | — | — | US | disclosed |
| WO-2011045383-A2 | 2, 6 -DIAMINOPYRIDINE COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH AMYLOID PROTEINS OR FOR TREATING OCULAR DISEASES | AC IMMUNE S.A. (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | AC IMMUNE S.A. (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | AC IMMUNE S.A. (CH) | 2011-04-21 | — | — | US | disclosed |
| EP-2311823-A1 | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases | AC Immune S.A. (CH) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | APP, CLN6, DPYSL2 | APP 1/4885CYP1A2 2029/4885HRH3 1798/4885 |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | APP, CLN6, DPYSL2 | APP 1/4885CYP1A2 2029/4885HRH3 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.